| dc.contributor.author | Aladag, Elifcan | |
| dc.contributor.author | Kelkitli, Engin | |
| dc.contributor.author | Goker, Hakan | |
| dc.date.accessioned | 2020-06-21T12:19:02Z | |
| dc.date.available | 2020-06-21T12:19:02Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1300-7777 | |
| dc.identifier.issn | 1308-5263 | |
| dc.identifier.uri | https://doi.org/10.4274/tjh.galenos.2019.2019.0157 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/10333 | |
| dc.description | WOS: 000514819900001 | en_US |
| dc.description | PubMed: 31475512 | en_US |
| dc.description.abstract | Graft-versus-host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD (aGvHD) is seen after alloHSCT and the incidence of aGvHD is around 30%-50%. aGvHD prophylaxis is essential in patients undergoing allo-HSCT. Initial therapy for aGvHD is steroids. Prognosis is poor in aGvHD patients not responding to steroids. In this article, the pathobiology, clinical findings, prophylaxis, and treatment of aGvHD will be summarized. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Galenos Yayincilik | en_US |
| dc.relation.isversionof | 10.4274/tjh.galenos.2019.2019.0157 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Graft-versus-host disease | en_US |
| dc.subject | Acute | en_US |
| dc.subject | Chronic | en_US |
| dc.title | Acute Graft-Versus-Host Disease: A Brief Review | en_US |
| dc.type | review | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 37 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 1 | en_US |
| dc.identifier.endpage | 4 | en_US |
| dc.relation.journal | Turkish Journal of Hematology | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
